Rasagiline preclinical studies: Implications for neuroprotection

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Rasagiline, a second-generation, irreversible, selective monoamine oxidase type B inhibitor, has demonstrated neuroprotective activity in both in vitro and in vivo models relevant to Parkinson disease. Available evidence suggests that rasagiline may facilitate dopaminergic cell survival by a variety of molecular mechanisms that prevent mitochondrial dysfunction, counteract oxidative stress, and modulate other potential mediators of apoptotic cell death. It remains unproven whether the preclinical neuroprotective activity of rasagiline is also evident in the clinical setting, although results of a delayed-start monotherapy trial in patients with early disease suggest it may have disease-modifying effects.

Original languageEnglish (US)
Pages (from-to)25-30
Number of pages6
Issue numberSUPPL.
StatePublished - Aug 1 2006

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Rasagiline preclinical studies: Implications for neuroprotection'. Together they form a unique fingerprint.

Cite this